Testing Blood For Circulating Tumor Cells Helps Inform Clinical Decisions About Treatments And Expensive Radiologic Scans
"The current standard of care for monitoring patients with metastatic breast cancer involves the use of radiology studies such as CT scans, ultrasounds, and the like to determine whether or not patients are deriving benefit from their current therapies." says Minetta Liu, M.D., lead investigator of the new analysis and director of translational breast cancer research at Georgetown Lombardi. "These tests can be expensive and invasive, and can negatively impact a patient's quality of life."
Liu says the new analysis substantiates the utility of the CTC test, which counts the number of CTCs in the blood. CTC results at or above the threshold of five are reliably associated with clinical and/or radiographic evidence of worsening disease, strengthening considerations for a change in therapy with the goal of improving long-term patient outcomes.
Enumerating CTCs can be done with various technologies. For this analysis, researchers culled data from peer-reviewed published studies, all of which, by chance, utilized the FDA-approved CellSearch™ technology. Teams from institutions around the world contributed blinded data to create a pooled dataset of 841 patients. This large sample size enabled Liu to confirm findings from other studies that indicate a CTC count of five or more is associated with disease progression. Importantly, the predictive value of CTCs was not affected by treatment type (chemotherapy, endocrine therapy, biologic therapy), tumor type (hormone receptor positive/negative, HER2 positive/negative), or sites of disease involvement.
"Using a blood test to count CTCs in addition to our existing tools for disease monitoring might improve our ability to appropriately treat patients and maximize their quality of life," explains Liu. "When a patient with metastatic breast cancer feels well and looks well, has had normal recent scans and CTC results that are consistently less than five, we feel more confident in her current treatment plan and may delay repeat imaging studies in favor of the less-invasive CTC blood test."
The study was conducted with no external funding. Liu reports receiving compensation for research-related speaking engagements on behalf of Veridex and various other pharmaceutical companies.
Georgetown University Medical Center
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Mallet, Karen. "Testing Blood For Circulating Tumor Cells Helps Inform Clinical Decisions About Treatments And Expensive Radiologic Scans." Medical News Today. MediLexicon, Intl., 19 May. 2011. Web.
30 May. 2017. <http://www.medicalnewstoday.com/releases/225822.php>
Mallet, K. (2011, May 19). "Testing Blood For Circulating Tumor Cells Helps Inform Clinical Decisions About Treatments And Expensive Radiologic Scans." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.